Finally, direct administration of endoxifen to bypass CYP2D6-dependent bio-activation and to reduce inter-individual variability of endoxifen Css levels (Ahmad et al. 2010) may be an attractive alternative in treatment of postmenopausal breast cancer. Here, CYP2D6 is linked to breast carcinoma.